Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat expansion reduce toxic DPR proteins and RNA foci, restoring nuclear TDP-43 localization and splicing function. This is the strongest hypothesis based on genetic prevalence (~40% familial ALS, ~25% FTD), active clinical trial data (NCT04165729), and mechanistic link between repeat transcripts and downstream TDP-43 pathology. Key unresolved questions include the relative contribution of haploinsufficiency vs. gain-of-function and whether TDP-43 inclusions represent a reversible state.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["C9orf72 Hexanucleotide G4C2 Repeat Expansion"]
B["Sense + Antisense RNA Foci Formation"]
C["DPR Proteins poly-GR / poly-PR"]
D["Nucleocytoplasmic Transport Impairment"]
E["Proteostasis Failure"]
F["Stress Granule Formation"]
G["Mitochondrial Dysfunction"]
H["Neurodegeneration ALS / FTD"]
A --> B
B --> C
B --> F
C --> D
D --> E
F --> E
E --> G
G --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
2
1
MECH 2CLIN 2GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
C9orf72 expansion accounts for ~40% familial ALS, …
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic Hypotheses in Neurodegeneration
Hypothesis 1: TREM2 Microglial Activation as Therapeutic Target in Alzheimer's Disease
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Neurodegeneration Therapeutic Hypotheses
Hypothesis 1: TREM2 Microglial Activation
Original Confidence: 0.78 → Revised: 0.62
Weak Links
Dose-dependency assumption unexamined. TREM2 signaling has a documented biphasic character — agonistic antibodies at high concentrations can cause receptor internalization and desensitization (Painter et al., 2018). The therapeutic window for 4D9 agonism is not established in the primary literature.
Mouse model confounding. The 5xFAD/Trem2−/− cross is problematic as a therapeutic-test platform: deleting TR
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
This assessment evaluates each hypothesis across five domains:
Druggability — tractability of the target and chemical matter
Biomarkers & Model Systems — readouts and experimental platforms available
Clinical-Development Constraints — regulatory, enrollment, and endpoint considerations
Safety — on-target and off-target liabilities
Timeline & Cost Realism — phase-appropriate milestones and resource requirements
Hypothesis 1: TREM2 Microglial Activation in AD
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD", "description": "Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat expansion reduce toxic DPR proteins and RNA foci, restoring nuclear TDP-43 localization and splicing function. This is the strongest hypothesis based on genetic prevalence (~40% familial ALS, ~25% FTD), active clinical trial data (NCT04165729), and mechanistic link between repeat transcripts and downstream TDP-43 pathology. Key unresolved questions include the relative contribution of haploinsuffic
IF C9orf72 ASOs (IONX-586 or equivalent) are administered to C9-BAC transgenic mice at 8 weeks of age (pre-symptomatic) for 12 weeks at 20 mg/kg via intracerebroventricular infusion, THEN CNS DPR protein levels (poly-GA, poly-GR, poly-PR) will decrease by ≥50% (measured by ELISA) AND nuclear TDP-43 fluorescence intensity will increase by ≥30% in motor neurons (measured by immunohistochemistry), compared to vehicle-treated controls.
pendingconf: 0.72
Expected outcome: ≥50% reduction in cortical/spinal cord DPR aggregates and ≥30% restoration of nuclear TDP-43 immunoreactivity in motor neurons within 12 weeks of treatment onset.
Falsified by: DPR protein levels unchanged or increased AND TDP-43 nuclear/cytoplasmic ratio shows no significant improvement (p>0.05) compared to vehicle, despite confirmed ASO uptake in CNS tissue.
Method: C9-BAC transgenic mice (line 100, Jackson Labs) treated with C9orf72-targeting ASO (sequence: 5'-mC*mU*mG*mC*mA*mG*mC*mU*mG*mC*mU*mC*mA*mC*mC*mC-3', 2'-MOE chemistry) via ICV osmotic pump. Endpoints: DPR ELISA (Millipore), TDP-43 IHC (Proteintech #60019-2-Ig) with confocal quantification. n=12 per group.
IF C9orf72 ASO treatment reduces DPR levels in patient-derived iPSC motor neurons from C9-ALS/FTD subjects, THEN exon 32 splicing of UNC13A (a validated TDP-43 target) will normalize to levels comparable to unaffected controls within 4 weeks of ASO exposure (10 μM, 14 days), with ≥40% restoration of normal splicing pattern.
pendingconf: 0.68
Expected outcome: UNC13A exon 32 inclusion ratio ≥0.75 (normalized to control lines) and restoration of normal neurite length and survival to ≥80% of control values.
Falsified by: UNC13A exon 32 splicing remains dysregulated (>20% deviation from disease baseline) AND neuronal survival shows no improvement despite confirmed DPR reduction (poly-GA ELISA) after ASO treatment.
Method: iPSC-derived motor neurons from 3 C9-ALS subjects (NINDS repository) and 3 CRISPR-corrected isogenic controls. ASO treatment (C9-targeting, 2'-MOE, 10 μM for 14 days). Outcomes: RT-PCR for UNC13A splicing (primers flanking exon 32), poly-GA ELISA (Mblr #2775), neurite length analysis (Neurite Quant). Primary replication in independent iPSC lines.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
Predicted Protein Structure
🔮
C9ORF72 — AlphaFold Prediction Q96LT7Click to expand 3D viewer
AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click